Technology
Moderna and Merck Cancer Vaccine Meets Phase 3 Trial Goals
Moderna and Merck announced that their personalized mRNA melanoma vaccine met its primary goals in a Phase 3 trial involving over 1,100 patients.
MarketsIndicesCommoditiesFXRates
